

10/520408

015 Rec'd PCT/PTO 03 JAN 2005

EXPRESS MAIL MAILING LABEL

NUMBER EV 414838625 US

DATE OF DEPOSIT January 3, 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Thomas P. Quinn and
Natalia G. Karasseva

Group Art Unit: Unknown

Examiner: Unknown

Serial No.: Unknown

Atty. Dkt. No.: UVMO:023US/SLH

Filed: Concurrently Herewith

For: ErbB-2 RECEPTOR TARGETING
PEPTIDE

STATEMENT AS REQUIRED UNDER 37 C.F.R. § 1.821(f)

MAIL STOP SEQUENCE

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450


Commissioner:

Submitted herewith is a computer readable form and a paper copy of the sequence listing of those sequences in the captioned patent application. The computer readable form of the sequence listing is the same as the paper copy of the sequence listing. The sequence information provided in the Specification is also the same as the sequence listing of the enclosed computer readable and paper forms of the sequence listing.

10/520408

DT15 Rec'd PCT/PTO 03 JAN 2005

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 536-3184

Date: January 3, 2005

SEQUENCE LISTING

<110> QUINN, THOMAS P.
KARASSEVA, NATALIA G.

<120> ErbB-2 RECEPTOR TARGETING PEPTIDE

<130> UVMO:023US

<140> UNKNOWN

<141> 2005-01-03

<150> PCT/US2003/021150

<151> 2003-07-03

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 1

Lys Cys Cys Tyr Ser Leu

1

5

<210> 2

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 2

Asp Tyr Lys Asp Asp Asp Asp Lys

1

5

<210> 3

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 3

Trp Tyr Ala Trp Met Leu

1

5

<210> 4
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 4
Trp Tyr Ser Trp Leu Leu
1 5

<210> 5
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 5
Cys Cys Tyr Thr Leu
1 5

<210> 6
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 6
Lys Cys Cys Phe Ser
1 5

<210> 7
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 7
Cys Cys Phe Ser Leu
1 5

<210> 8
<211> 20
<212> PRT
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
Peptide

<400> 8

Arg Arg Leu Leu Phe Tyr Lys Tyr Val Tyr Lys Arg Tyr Arg Ala Gly
1 5 10 15

Lys Gln Arg Gly
20